07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Bucillamine: Interim Phase IIa data

Interim data from 29 patients with acute gout flares in an open-label, U.S. Phase IIa trial showed that once-daily 900 and 1,800 mg oral REV-002 for 7 days led to a >=50% reduction in target...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

Bucillamine: Phase IIa start

At year end, Revive Therapeutics will begin an open-label, U.S. Phase IIa trial to evaluate a high- and moderate-dose of once-daily oral REV-002 in combination with low-dose colchicine for 7 days in about 66 patients....
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Revive Therapeutics deal

Revive signed a material transfer agreement with an undisclosed pharmaceutical company headquartered in Osaka, Japan, to gain access to confidential information and clinical trial supply of bucillamine for Revive's Phase IIa trial of REV-002 to...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Revive Therapeutics deal

Revive Therapeutics Inc. reverse-merged with shell company Mercury Capital II Ltd. to form Revive Therapeutics Ltd., which began trading under the symbol "RVV" on the TSX Venture. The newco issued 16.6 million shares to Revive...
07:00 , Jul 1, 2002 |  BC Week In Review  |  Clinical News

Keystone Biomedical Inc. preclinical data

Researchers published in the Proceedings of the National Academy of Sciences the use of bucillamine in treating TARI. The 30-day survival rate of bucillamine-treated rats that received a liver isograft was 100% (15/15), compared to...